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Neuroblate Fusion:
• Neuroblate Fusion is a robotically controlled laser 
therapy that also utilizes real-time MRI to ablate 
tumors.
• Neurosurgeons use intraoperative magnetic 
resonance imaging (iMRI) to create accurate images 
of the brain that guide them in removing brain 
tumors, such as glioblastomas. 
• Prior to the start of the procedure, the neurosurgeon 
plans the surgical approach and chooses which 
probe would work best.
• The patient is then transferred to the operating suite 
with their head remaining stabilized.
• Under MRI guidance, the surgeon accurately places 
the probe and delivers the laser energy to ablate the 
area of interest. If necessary, a second trajectory can 
be made using a single laser probe.
• Neuroblate Fusion is a minimally invasive 
procedure and is tolerated very well by patients. 
Most patients are discharged quickly, have a short 
recovery time, and only have 1-2 stitches. 
Follow-up MRI images of the tumor begin to 
show evidence of tumor death immediately after 
the procedure.
• Indications for the use of Neuroblate Fusion include 
the size, shape, and location of the tumor.
Neuroblate Fusion vs. Craniotomy: 
Statistics: 
• A research study was done to show the outcomes of 
survival in patients with glioblastomas who undergo 
LITT.
• 17 research articles were found with a total of 203 
patients with recurrent glioblastomas who 
underwent 219 LITT procedures.
• The morbidity rate was only 6.4%. Zero deaths 
reported related to the LITT procedure.
• Average overall survival rate after the initial 
diagnosis was 14.7 months. (Montemurro, 2020, p. 
2)
• Without treatment for glioblastoma, the average 
survival is only a few months, but even with 
treatment survival is usually around 1 year.
• For patients who have surgery to resect the tumor 
along with chemotherapy or radiation therapy, the 
overall survival is still only about 14 months. 
(Eldridge, 2020, p. 3)
Conclusion: 
Overall, Neuroblate Fusion is beneficial for treating 
aggressive tumors such as glioblastomas. It is a 
minimally invasive alternative to traditional brain 
surgery. Research demonstrates that laser therapy is 
safe and the overall survival rate for patients is high. 
With the Neuroblate system proving to be effective, we 
are continuing to provide new hope to patients 
suffering with glioblastomas. Real-time MRI laser 
therapy allows neurosurgeons to accurately assess the 
tumors and plan out the ablation process. In the future, 
medical professionals will continue to create better 
MRI technology that will improve patient care and 
patient’s quality of life. Neuroblate Fusion is relatively 
new and is not readily available in every facility. 
Researchers are exploring a more widespread use of 
laser therapy throughout the world to become the gold 
standard of treatment of glioblastomas.
Introduction: 
The Neuroblate Fusion system utilizes magnetic 
resonance guided laser therapy to ablate tumors and 
lesions. The system requires the use of Laser Interstitial 
Thermo Therapy (LITT) to activate thermocoagulation 
and focus of tissue destruction. This is a minimally 
invasive alternative to traditional brain surgery, giving 
patients a shorter recovery time and fewer 
complications. Neuroblate Fusion may also be an 
additional treatment to chemotherapy or radiation 
therapy. Neuroblate Fusion is best used for treating 
glioblastomas in the brain and occasionally for 
reducing the potential for seizures. Under sterile 
conditions, a small burr hole is made in the patient’s 
skull which allows the neurosurgeon to accurately place 
the probe onto the area of interest. Concurrently with 
the surgical procedure, real-time magnetic resonance 
imaging (MRI) is performed. This helps to assist the 
surgeons in precisely locating the glioblastoma and 
destroy the carcinogenic tissues with the laser, while 
avoiding the surrounding healthy tissues and anatomy. 
Neuroblate Fusion is a great treatment option for 
patients who are suffering with aggressive tumors such 
as glioblastomas. Laser therapy gives patients a new 
hope and a better chance of survival. Recurrence of 
glioblastomas are common after patients undergo a first 
surgery without the use of Neuroblate Fusion. 
Destroying the tumor proves to be more successful 
after a second surgery is done using laser therapy. In 
the future, Neuroblate Fusion may become the gold 
standard for treating glioblastomas. 
The Role of MRI:  
• The Neuroblate Fusion System was approved by the 
FDA in 2009. (University Hospitals, 2020, p. 1)
• In 2020, Monteris Medical announced FDA 
clearance of it’s Neuroblate Fusion-S Software. 
(Biospace, 2020, p. 1)
Private company that develops LITT.
• Prior to the MRI of the brain, a computed 
tomography (CT) scan of the brain is done to locate 
the tumor(s).
• Contrast enhanced MRI remains the primary form of 
imaging to assess the size and spread of brain 
tumors. 
• In contrast enhanced MRI for the evaluation of a  
glioblastoma, both inflammation and any abnormal 
vasculature will be demonstrated.
• a defining pathologic feature of glioblastomas is 
the presence of thick, irregular nodules. (Schmitt & 
Stein, 2016, p. 87)
• Real-time MRI helps to assist in the surgical 
intervention and treatment of tumors.
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Figure 2. Axial MR images of a brain with a glioblastoma 
pre-operative and 24-hour post-operative (see arrows)
Figure 3. Neuroblate Fusion probe being 
used in an OR suite
Glioblastoma: 
• A glioblastoma is a rare, life-threatening brain 
tumor that originates in the glial cells of the brain 
or spinal cord.
• Glioblastomas are generally found in the cerebral 
hemispheres of the brain.
• Common symptoms of having a glioblastoma 
include headache, memory loss, seizures, speech 
and balance difficulties, and confusion. (Newman, 
2018, p. 3)
• The exact cause is unknown.
• Factors that increase the risk of having a 
glioblastoma include age (most common), radiation 
exposure, and family history.
Age 60 years and older have a higher likelihood 
of glioblastoma.
• Treatments include Neuroblate Fusion, 
chemotherapy to stop the cancerous cell growth, 
target drug therapy to suppress the abnormalities, 
tumor excision for removal, and radiation therapy 
to destroy the abnormal cells.
Figure 4. Robotic probe attached to 











• Minimally invasive 
• A small burr hole is made 
to insert the probe
• Risks such as bleeding, 
infection, edema, tissue 
damage, and hematoma are 
less likely to occur 
(Monteris Medical, 2021, p. 5)
• Average hospital stay is 
about 3.5 days (Montemurro, 
2020, p. 2) 
• Is the standard surgery for 
most brain tumors 
• A section of the skull is 
removed to access the 
tumor
• Risks such as bleeding, 
infection, edema, tissue 
damage, and hematoma are 
more likely to occur







Figure 1. Axial MR image of a 
normal brain without a glioblastoma
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